Abstract
Atherosclerosis is a chronic process related to several underlying mechanisms leading to the formation and evolution of atherosclerotic plaque. Of great interest are during the last years short, non-coding RNAs, called microRNAs and responsible for several aspects of homeostasis and disease. According to the available data microRNAs are expressed in the cardiovascular system and have key roles in normal states, as well as in disease development and progression. Moreover, it has been shown that they contribute to atherogenesis, coronary artery disease and myocardial infarction. Importantly, microRNAs circulate in the bloodstream, while they exist in tissues, affect plaque initiation and progression and seem to be essential biomarkers of atherosclerosis. Therefore, understanding the role of these molecules may be of great importance in the understanding of the pathogenesis of atheromatous plaque providing new evidence for diagnosis and treatment of atherosclerosis and its' clinical presentation.
Keywords: miRNAs, atherosclerosis, plaque progression, non-coding RNAs, homeostasis, coronary artery disease, myocardial infarction, biomarkers, cardiovascular system, plaque initiation
Current Pharmaceutical Design
Title:The Role of microRNAs in the Initiation and Progression of Stable Atheromatous Plaque
Volume: 19 Issue: 9
Author(s): Nikolaos Papageorgiou, Dimitris Tousoulis, Emmanuel Androulakis, Anna Kontogeorgou, Marietta Charakida, Anastasios Giolis, Katerina Siama, Athanasios Trikas, Alexandros Briasoulis, Christos Pitsavos and Christodoulos Stefanadis
Affiliation:
Keywords: miRNAs, atherosclerosis, plaque progression, non-coding RNAs, homeostasis, coronary artery disease, myocardial infarction, biomarkers, cardiovascular system, plaque initiation
Abstract: Atherosclerosis is a chronic process related to several underlying mechanisms leading to the formation and evolution of atherosclerotic plaque. Of great interest are during the last years short, non-coding RNAs, called microRNAs and responsible for several aspects of homeostasis and disease. According to the available data microRNAs are expressed in the cardiovascular system and have key roles in normal states, as well as in disease development and progression. Moreover, it has been shown that they contribute to atherogenesis, coronary artery disease and myocardial infarction. Importantly, microRNAs circulate in the bloodstream, while they exist in tissues, affect plaque initiation and progression and seem to be essential biomarkers of atherosclerosis. Therefore, understanding the role of these molecules may be of great importance in the understanding of the pathogenesis of atheromatous plaque providing new evidence for diagnosis and treatment of atherosclerosis and its' clinical presentation.
Export Options
About this article
Cite this article as:
Papageorgiou Nikolaos, Tousoulis Dimitris, Androulakis Emmanuel, Kontogeorgou Anna, Charakida Marietta, Giolis Anastasios, Siama Katerina, Trikas Athanasios, Briasoulis Alexandros, Pitsavos Christos and Stefanadis Christodoulos, The Role of microRNAs in the Initiation and Progression of Stable Atheromatous Plaque, Current Pharmaceutical Design 2013; 19 (9) . https://dx.doi.org/10.2174/1381612811319090012
DOI https://dx.doi.org/10.2174/1381612811319090012 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Perspectives on New Synthetic Curcumin Analogs and their Potential Anticancer Properties
Current Pharmaceutical Design Psychosocial Risk Factors Related to Ischemic Heart Disease in Women
Current Pharmaceutical Design Biomarkers of Senescence during Aging as Possible Warnings to Use Preventive Measures
Current Medicinal Chemistry ACE Inhibition of Plant Alkaloids Targeted Approach for Selective Inhibition
Mini-Reviews in Organic Chemistry Domperidone in Parkinson’s Disease: A Perilous Arrhythmogenic or the Gold Standard?
Current Drug Safety Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling
Current Pharmaceutical Design Microvascular Diseases: Is A New Era Coming?
Cardiovascular & Hematological Agents in Medicinal Chemistry Subject Index To Volume 6
Cardiovascular & Hematological Disorders-Drug Targets Telmisartan in the Management of Diabetic Nephropathy: A Contemporary View
Current Diabetes Reviews Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review
Current Molecular Medicine HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
Current Pharmaceutical Design Optimization of Important Early ADME(T) Parameters of NADPH Oxidase-4 Inhibitor Molecules
Medicinal Chemistry Regulation of Mitochondrial Function and its Impact in Metabolic Stress
Current Medicinal Chemistry Aliskiren, a Direct Renin Inhibitor, in Clinical Practice: A New Approach in the Treatment of Hypertension
Current Vascular Pharmacology Stem Cells and Cardiovascular Repair: A Role for Natural and Synthetic Molecules Harboring Differentiating and Paracrine Logics
Cardiovascular & Hematological Agents in Medicinal Chemistry Renal Protective Effect of Metabolic Therapy in Patients with Coronary Artery Disease and Diabetes: From Bench to Bed Side
Current Pharmaceutical Design Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Sacubitril-Valsartan Improves Anemia of Cardiorenal Syndrome (CRS)
Cardiovascular & Hematological Agents in Medicinal Chemistry From Bone Marrow to Cardiac Atrial Appendage Stem Cells for Cardiac Repair: A Review
Current Medicinal Chemistry